FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W204526616> ?p ?o ?g. }

• W204526616 endingPage "4" @default.
• W204526616 startingPage "610" @default.
• W204526616 abstract "To evaluate the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from HLA-matched sibling donor (MSD allo-HSCT) for severe aplastic anemia (SAA).The clinical data of 41 SAA patients received MSD allo-HSCT from May. 2003 to Aug. 2011 were analyzed retrospectively. 24 patients were male, 17 were female. Median age was 23 (5 - 43) years old. 28 patients had SAA-I, 9 had SAA-II, and 4 had post-hepatitis aplastic anemia. 17 patients received allogeneic bone marrow (BM) transplantation (allo-BMT), and 24 received allogeneic peripheral blood stem cell (PBSC) transplantation (allo-PBSCT). The conditioning regimens: 20 patients received cyclophosphamide (CY) + anti-thymocyte globulin (ATG) + fludarabine (Flu), 21 received CY + ATG + Flu+ cytarabine (Ara-C) ± busulfan (Bu)/melphalan (Mel). Prophylaxis for graft-versus-host disease (GVHD): 25 patients received cyclosporine (CSA) plus short-term methotrexate (MTX), 16 received tacrolimus (FK506) plus short-term MTX. The median number of infused CD34(+) cells were 3.48 (2.39 - 4.80)×10(6)/kg in allo-BMT and 2.95 (1.27 - 5.98)×10(6)/kg in allo-PBSCT, respectively.Hematopoietic reconstitution was observed in all 41 patients (100%). The median time of neutrophils (ANC) reached to 0.5×10(9)/L and platelets (PLT) reached to 20×10(9)/L were 14 (10 - 23) days and 19 (8 - 38) days, respectively. 12 patients developed acute GVHD (aGVHD), out of which 11 developed grade I-II aGVHD, and one developed grade IV. 2 patients occurred chronic GVHD (cGVHD), out of which one with local cGVHD and the other with extensive. 4 patients occurred graft rejection (GR), all of them recovered haemopoiesis and survived after donor PBSC infusion. 5 patients (12.2%) died, out of which one died of extensive cGVHD, and 4 died of invasive fungal infections (IFI). Median follow-up time was 23 (3 - 79) months. 36 patients survived. 5-year estimated overall survival (OS), disease free survival (DFS), and transplant-related mortality (TRM) was (81.1 ± 9.0)%, (68.4 ± 11.0)%, and (18.9 ± 9.0)%, respectively. Univariate analysis showed that lover OS had significant correlation with receiving PBSCT, occurrence of aGVHD, the number of infused CD34(+) cells no more than 2.5×10(6)/kg, the number of red blood cell (RBC) transfusion before transplant more than 30 U and occurrence of IFI after transplantation (P = 0.034, 0.001, 0.006, 0.000, 0.001, respectively). Occurrence of aGVHD had significant correlation with the disparity between donor and recipient ABO blood groups, the number of PLT transfusion more than 100 U, and the number of RBC transfusion more than 30 U before transplantation, the number of infused CD34(+) cells no more than 2.5× 10(6)/kg (P = 0.019, 0.038, 0.005, 0.005, respectively). The occurrence of GR had significant correlation with the number of PLT transfusion more than 100 U before transplantation (P = 0.038).MSD allo-HSCT is an effective therapy for patients with SAA. Lower number of blood transfusion before transplantation, use of BMT, more number of infused CD34(+) cells can effectively prevent and treat aGVHD and IFI after transplantation, which may improve the efficacy of MSD allo-HSCT for SAA." @default.
• W204526616 created "2016-06-24" @default.
• W204526616 creator A5003460402 @default.
• W204526616 creator A5015501839 @default.
• W204526616 creator A5019511355 @default.
• W204526616 creator A5023579469 @default.
• W204526616 creator A5028462736 @default.
• W204526616 creator A5029862222 @default.
• W204526616 creator A5030090551 @default.
• W204526616 creator A5033405514 @default.
• W204526616 creator A5058059511 @default.
• W204526616 creator A5060911926 @default.
• W204526616 creator A5073978108 @default.
• W204526616 creator A5074779796 @default.
• W204526616 date "2012-08-01" @default.
• W204526616 modified "2023-09-23" @default.
• W204526616 title "[Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia]." @default.
• W204526616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23134851" @default.
• W204526616 hasPublicationYear "2012" @default.
• W204526616 type Work @default.
• W204526616 sameAs 204526616 @default.
• W204526616 citedByCount "3" @default.
• W204526616 countsByYear W2045266162015 @default.
• W204526616 countsByYear W2045266162016 @default.
• W204526616 countsByYear W2045266162022 @default.
• W204526616 crossrefType "journal-article" @default.
• W204526616 hasAuthorship W204526616A5003460402 @default.
• W204526616 hasAuthorship W204526616A5015501839 @default.
• W204526616 hasAuthorship W204526616A5019511355 @default.
• W204526616 hasAuthorship W204526616A5023579469 @default.
• W204526616 hasAuthorship W204526616A5028462736 @default.
• W204526616 hasAuthorship W204526616A5029862222 @default.
• W204526616 hasAuthorship W204526616A5030090551 @default.
• W204526616 hasAuthorship W204526616A5033405514 @default.
• W204526616 hasAuthorship W204526616A5058059511 @default.
• W204526616 hasAuthorship W204526616A5060911926 @default.
• W204526616 hasAuthorship W204526616A5073978108 @default.
• W204526616 hasAuthorship W204526616A5074779796 @default.
• W204526616 hasConcept C126322002 @default.
• W204526616 hasConcept C203014093 @default.
• W204526616 hasConcept C2776694085 @default.
• W204526616 hasConcept C2776755627 @default.
• W204526616 hasConcept C2777408962 @default.
• W204526616 hasConcept C2779263901 @default.
• W204526616 hasConcept C2779972918 @default.
• W204526616 hasConcept C2780007613 @default.
• W204526616 hasConcept C2780611847 @default.
• W204526616 hasConcept C2781440808 @default.
• W204526616 hasConcept C2909675724 @default.
• W204526616 hasConcept C2911091166 @default.
• W204526616 hasConcept C71924100 @default.
• W204526616 hasConcept C90924648 @default.
• W204526616 hasConceptScore W204526616C126322002 @default.
• W204526616 hasConceptScore W204526616C203014093 @default.
• W204526616 hasConceptScore W204526616C2776694085 @default.
• W204526616 hasConceptScore W204526616C2776755627 @default.
• W204526616 hasConceptScore W204526616C2777408962 @default.
• W204526616 hasConceptScore W204526616C2779263901 @default.
• W204526616 hasConceptScore W204526616C2779972918 @default.
• W204526616 hasConceptScore W204526616C2780007613 @default.
• W204526616 hasConceptScore W204526616C2780611847 @default.
• W204526616 hasConceptScore W204526616C2781440808 @default.
• W204526616 hasConceptScore W204526616C2909675724 @default.
• W204526616 hasConceptScore W204526616C2911091166 @default.
• W204526616 hasConceptScore W204526616C71924100 @default.
• W204526616 hasConceptScore W204526616C90924648 @default.
• W204526616 hasIssue "8" @default.
• W204526616 hasLocation W2045266161 @default.
• W204526616 hasOpenAccess W204526616 @default.
• W204526616 hasPrimaryLocation W2045266161 @default.
• W204526616 hasRelatedWork W2031399468 @default.
• W204526616 hasRelatedWork W204526616 @default.
• W204526616 hasRelatedWork W2091691319 @default.
• W204526616 hasRelatedWork W2495201617 @default.
• W204526616 hasRelatedWork W2560664961 @default.
• W204526616 hasRelatedWork W2570187106 @default.
• W204526616 hasRelatedWork W2593968947 @default.
• W204526616 hasRelatedWork W2735009751 @default.
• W204526616 hasRelatedWork W2766769088 @default.
• W204526616 hasRelatedWork W3032022537 @default.
• W204526616 hasVolume "33" @default.
• W204526616 isParatext "false" @default.
• W204526616 isRetracted "false" @default.
• W204526616 magId "204526616" @default.
• W204526616 workType "article" @default.